|Bid||266.90 x 60500|
|Ask||266.90 x 66200|
|Day's range||266.50 - 271.40|
|52-week range||203.30 - 278.40|
|PE ratio (TTM)||25.17|
|Earnings date||25 Jul 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||287.90|
Swiss drugmaker-for-hire Lonza is betting that trillions of customized viruses made at a giant factory in Texas will be the lucrative raw materials of a medical revolution. When its 250,000-square-ft Houston plant opens on Tuesday, it will be able to mass produce key components for emerging gene and cell therapies to treat everything from blindness to cancer. As the industry grapples with a shortage of engineered viruses needed to transport healthy gene material into the cells of sick people, Lonza is calculating demand will remain strong, from cash-strapped early-stage companies to more established clients fearful of getting caught in the squeeze.
Lonza forecast a 2018 operating profit margin that fell short of market expectations on Wednesday, knocking the Swiss drug ingredients maker's shares despite its 2017 earnings beating predictions. Shares (Berlin: DI6.BE - news) in Lonza, which makes molecules for drug companies such as Roche as well as ingredients for nutritional supplements, were down 3.8 percent to 264.70 Swiss francs at 1305 GMT. Some analysts said they were underwhelmed by Chief Executive Richard Ridinger's goal for achieving a 100 basis point improvement in core margin for earnings before interest, taxes, depreciation and amortisation (EBITDA).